Maintenance Notice

Due to necessary scheduled maintenance, the JMIR Publications website will be unavailable from Wednesday, July 01, 2020 at 8:00 PM to 10:00 PM EST. We apologize in advance for any inconvenience this may cause you.

Who will be affected?

Accepted for/Published in: JMIR Research Protocols

Date Submitted: Dec 1, 2020
Date Accepted: Apr 19, 2021

The final, peer-reviewed published version of this preprint can be found here:

Home Telemonitoring of Arterial Hypertension With Antihypertensive Treatment Titration: Protocol for a Randomized Controlled Prospective Trial (HOROSCOPE Study)

Ben Hafaiedh S, Ben Daya Y, Radoui AH, Bouchoucha M, Razgallah R, Nouira S

Home Telemonitoring of Arterial Hypertension With Antihypertensive Treatment Titration: Protocol for a Randomized Controlled Prospective Trial (HOROSCOPE Study)

JMIR Res Protoc 2022;11(3):e26184

DOI: 10.2196/26184

PMID: 35230254

PMCID: 8924775

Home Telemonitoring of Arterial Hypertension with Antihypertensive Treatment Titration: Protocol of a Randomized Controlled Prospective Trial (HOROSCOPE Study)

  • SONIA Ben Hafaiedh; 
  • Yosra Ben Daya; 
  • Amina Hadjer Radoui; 
  • Mohamed Bouchoucha; 
  • Rabie Razgallah; 
  • Semir Nouira

ABSTRACT

Background:

Despite the availability of effective treatment, the control of hypertension remains insufficient. Telemonitoring in the management of hypertension would be an effective way to improve blood pressure (BP) control.

Objective:

The aim of this study is to evaluate the effects of telemonitoring with anti-hypertensive treatment titration on blood pressure control in Tunisian hypertensive patients.

Methods:

It will be a prospective, rater blinded, randomized, controlled trial carried out with primary care physicians in the Sahel region of Tunisia. Patients will be eligible for enrolment if they are over 35 years of age, newly diagnosed with hypertension, or known to be poorly controlled on antihypertensive therapy. Participants will be randomly assigned in a 1:1 ratio to the telemonitoring or usual care arm. The telemonitoring arm involves of a weekly telephone call for collection of the home BP measurements, therapeutic education, treatment compliance assessment, as well as having a monthly call for treatment titration and side effects check. Randomization will be done by use of interactive web responsive system (IWRS) and will be stratified by investigation centers. Neither participants nor investigators will be masked to groups’ assignment. The primary outcome is the change from baseline in the 2 groups of mean 24-hour systolic blood pressure (SBP) at 6 months of follow-up. All randomized patients who will attend the follow-up visit at 6 months and have no missing data for the primary outcome will be included in the analysis.

Results:

Recruitment to the trial started in July 2020. The study was initiated with 17 primary care physicians. We expect the inclusion period to last for approximately 6 months. We expect to complete data collection at the end of 2021 and plan the dissemination of the results subsequently.

Conclusions:

The HOROSCOPE trial will provide important new evidence that could shed some light on the feasibility and impact of telemonitoring along with self-monitoring in a Tunisian hypertensive population consulting in primary care. Clinical Trial: Trial Registration: ClinicalTrials.gov identifier: NCT04607239;


 Citation

Please cite as:

Ben Hafaiedh S, Ben Daya Y, Radoui AH, Bouchoucha M, Razgallah R, Nouira S

Home Telemonitoring of Arterial Hypertension With Antihypertensive Treatment Titration: Protocol for a Randomized Controlled Prospective Trial (HOROSCOPE Study)

JMIR Res Protoc 2022;11(3):e26184

DOI: 10.2196/26184

PMID: 35230254

PMCID: 8924775

Download PDF


Request queued. Please wait while the file is being generated. It may take some time.

© The authors. All rights reserved. This is a privileged document currently under peer-review/community review (or an accepted/rejected manuscript). Authors have provided JMIR Publications with an exclusive license to publish this preprint on it's website for review and ahead-of-print citation purposes only. While the final peer-reviewed paper may be licensed under a cc-by license on publication, at this stage authors and publisher expressively prohibit redistribution of this draft paper other than for review purposes.